Cargando…

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality

Detalles Bibliográficos
Autores principales:	Du, Lixin, Qin, Jiao, Wang, Dengchuan, Zhao, Yunhui, Xu, Ning, Wu, Chaowen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386073/ https://www.ncbi.nlm.nih.gov/pubmed/35990975 http://dx.doi.org/10.3389/fcvm.2022.987025

Ejemplares similares

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
por: Dzaye, Omar, et al.
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
por: Xi, Yangbo, et al.
Publicado: (2022)

GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
por: Qiu, Mei, et al.
Publicado: (2020)

SAT-LB013 The Effect of Select GLP1 Agonists and SGLT2 Inhibitors on the Unfolded Protein Response in Primary Human Coronary Artery Endothelial Cells
por: Kalidas, Poonam, et al.
Publicado: (2019)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Inflammation index SIRI is associated with increased all-cause and cardiovascular mortality among patients with hypertension
por: Zhao, Songfeng, et al.
Publicado: (2023)

Association of Total Bilirubin With All-Cause and Cardiovascular Mortality in the General Population
por: Chen, Ziwei, et al.
Publicado: (2021)

The association of central and extremity circumference with all-cause mortality and cardiovascular mortality: a cohort study
por: Liu, Jiajun, et al.
Publicado: (2023)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Estimated pulse wave velocity is associated with all-cause mortality and cardiovascular mortality among adults with diabetes
por: Wu, Li-Da, et al.
Publicado: (2023)

Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
por: Nayak, Agnish, et al.
Publicado: (2018)

Impact of Physical Activity on All-Cause Mortality According to Specific Cardiovascular Disease
por: Kim, Moon-Hyun, et al.
Publicado: (2022)

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality
por: Ng, Cheng Han, et al.
Publicado: (2022)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Association between FIB-4, all-cause mortality, cardiovascular mortality, and cardiovascular disease risk among diabetic individuals: NHANES 1999–2008
por: Guan, Lihua, et al.
Publicado: (2023)

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
por: Mazzieri, Alessio, et al.
Publicado: (2023)

Sodium and potassium intake and risk of cardiovascular events and all-cause mortality: the Rotterdam Study
por: Geleijnse, Johanna M., et al.
Publicado: (2007)

Association of nighttime physical activity with all-cause and cardiovascular mortality: Results from the NHANES
por: Yi, Jiayi, et al.
Publicado: (2022)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

Association Between Asthma and All-Cause Mortality and Cardiovascular Disease Morbidity and Mortality: A Meta-Analysis of Cohort Studies
por: Zhang, Bin, et al.
Publicado: (2022)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Association of the systemic immune-inflammation index with all-cause mortality in patients with arteriosclerotic cardiovascular disease
por: He, Lu, et al.
Publicado: (2022)

The Association Between Exposure to Acrylamide and Mortalities of Cardiovascular Disease and All-Cause Among People With Hyperglycemia
por: Wu, Huanyu, et al.
Publicado: (2022)

Serum C-peptide level and the risk of cardiovascular diseases mortality and all-cause mortality: a meta-analysis and systematic review
por: Ahmadirad, Hamid, et al.
Publicado: (2023)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2018)

Combined effects of physical activity and sedentary behavior on all-cause mortality in heart failure patients: A cohort study of national health and nutrition examination survey analysis
por: Zhu, Yunhui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c76hfr912qtf2dcmtihairskm9